Literature DB >> 19284718

Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.

Sung Jin Cho1, Niels H Jensen, Toru Kurome, Sudhakar Kadari, Michael L Manzano, Jessica E Malberg, Barbara Caldarone, Bryan L Roth, Alan P Kozikowski.   

Abstract

We report here the design, synthesis, and pharmacological properties of a series of compounds related to tranylcypromine (9), which itself was discovered as a lead compound in a high-throughput screening campaign. Starting from 9, which shows modest activity as a 5-HT(2C) agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT(2C) agonists through iterative structural modifications. Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring. Among the tested compounds, several were potent and efficacious 5-HT(2C) receptor agonists with selectivity over both 5-HT(2A) and 5-HT(2B) receptors in functional assays. The most promising compound is 37, with 120- and 14-fold selectivity over 5-HT(2A) and 5-HT(2B), respectively (EC(50) = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, respectively). In animal studies, compound 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284718      PMCID: PMC2832311          DOI: 10.1021/jm801354e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

Review 1.  G-protein-coupled receptors at a glance.

Authors:  Wesley K Kroeze; Douglas J Sheffler; Bryan L Roth
Journal:  J Cell Sci       Date:  2003-12-15       Impact factor: 5.285

2.  Assessing scoring functions for protein-ligand interactions.

Authors:  Philippe Ferrara; Holger Gohlke; Daniel J Price; Gerhard Klebe; Charles L Brooks
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

Review 3.  The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis.

Authors:  W K Kroeze; B L Roth
Journal:  Biol Psychiatry       Date:  1998-12-01       Impact factor: 13.382

4.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.

Authors:  J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

5.  Chemical and biological properties of some aminomethyl-2-phenylcyclopropane derivatives. Pharmacological comparison with tranylcypromine.

Authors:  U M Teotino; D D Bella; A Gandini; G Benelli
Journal:  J Med Chem       Date:  1967-11       Impact factor: 7.446

6.  Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice.

Authors:  Beatriz A Rocha; Evan H Goulding; Laura E O'Dell; Andy N Mead; Nicole G Coufal; Loren H Parsons; Laurence H Tecott
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

7.  Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines.

Authors:  G S Welmaker; J A Nelson; J E Sabalski; A L Sabb; J R Potoski; D Graziano; M Kagan; J Coupet; J Dunlop; H Mazandarani; S Rosenzweig-Lipson; S Sukoff; Y Zhang
Journal:  Bioorg Med Chem Lett       Date:  2000-09-04       Impact factor: 2.823

8.  Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors.

Authors:  J F Cryan; I Lucki
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

9.  Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.

Authors:  Dean A Wacker; Jeffrey G Varnes; Sarah E Malmstrom; Xueying Cao; Chen-Pin Hung; Thao Ung; Ginger Wu; Ge Zhang; Eva Zuvich; Michael A Thomas; William J Keim; Mary Jane Cullen; Kenneth W Rohrbach; Qinling Qu; Rangaraj Narayanan; Karen Rossi; Evan Janovitz; Lois Lehman-McKeeman; Mary F Malley; James Devenny; Mary Ann Pelleymounter; Keith J Miller; Jeffrey A Robl
Journal:  J Med Chem       Date:  2007-02-23       Impact factor: 7.446

10.  Fluorinated phenylcyclopropylamines. 1. Synthesis and effect of fluorine substitution at the cyclopropane ring on inhibition of microbial tyramine oxidase.

Authors:  Shinichi Yoshida; Oliver G J Meyer; Thomas C Rosen; Günter Haufe; Song Ye; Milton J Sloan; Kenneth L Kirk
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

View more
  14 in total

1.  HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.

Authors:  Alan P Kozikowski; Sung Jin Cho; Niels H Jensen; John A Allen; Andreas M Svennebring; Bryan L Roth
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

2.  Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.

Authors:  Gang Chen; Sung Jin Cho; Xi-Ping Huang; Niels H Jensen; Andreas Svennebring; Maria F Sassano; Bryan L Roth; Alan P Kozikowski
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

3.  Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.

Authors:  Bryan L Roth
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

4.  Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.

Authors:  Christopher T Wild; Joanna M Miszkiel; Eric A Wold; Claudia A Soto; Chunyong Ding; Rachel M Hartley; Mark A White; Noelle C Anastasio; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-04-13       Impact factor: 7.446

5.  Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.

Authors:  Jianjun Cheng; Patrick M Giguère; Oluseye K Onajole; Wei Lv; Arsen Gaisin; Hendra Gunosewoyo; Claire M Schmerberg; Vladimir M Pogorelov; Ramona M Rodriguiz; Giulio Vistoli; William C Wetsel; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2015-02-10       Impact factor: 7.446

6.  Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism.

Authors:  Guiping Zhang; John D McCorvy; Sida Shen; Jianjun Cheng; Bryan L Roth; Alan P Kozikowski
Journal:  Eur J Med Chem       Date:  2019-08-14       Impact factor: 6.514

7.  Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.

Authors:  Rossella Fioravanti; Annalisa Romanelli; Nicola Mautone; Elisabetta Di Bello; Annarita Rovere; Davide Corinti; Clemens Zwergel; Sergio Valente; Dante Rotili; Oronza A Botrugno; Paola Dessanti; Stefania Vultaggio; Paola Vianello; Anna Cappa; Claudia Binda; Andrea Mattevi; Saverio Minucci; Ciro Mercurio; Mario Varasi; Antonello Mai
Journal:  ChemMedChem       Date:  2020-02-14       Impact factor: 3.466

8.  Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.

Authors:  Jianjun Cheng; Patrick M Giguere; Claire M Schmerberg; Vladimir M Pogorelov; Ramona M Rodriguiz; Xi-Ping Huang; Hu Zhu; John D McCorvy; William C Wetsel; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-01-13       Impact factor: 7.446

9.  Design, synthesis and biological evaluation of GPR55 agonists.

Authors:  Lara Fakhouri; Christopher D Cook; Mohammed H Al-Huniti; Linda M Console-Bram; Dow P Hurst; Michael B S Spano; Daniel J Nasrallah; Marc G Caron; Larry S Barak; Patricia H Reggio; Mary E Abood; Mitchell P Croatt
Journal:  Bioorg Med Chem       Date:  2017-06-13       Impact factor: 3.641

10.  We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.

Authors:  Jianjun Cheng; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2015-10-28       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.